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CASE REPORTSAortic wall papillary fibroelastomaJose Marıa Gonzalez-Santos, PhD,a Marıa Elena Arnaiz-Garcıa, MD,a
Marıa del Carmen Vargas-Fajardo, PhD,b and Antonio Arribas-Jimenez, PhD,c Salamanca, SpainPapillary fibroelastomas are rare tumors usually involving
the cardiac valves. We present an extremely rare case of
a papillary fibroelastoma originating from the aortic wall.
The patient was successfully treated with complete tumor
resection and a valve-sparing procedure to restore the aortic
root anatomy.CLINICAL SUMMARY
A 77-year-old woman was admitted to the University
Hospital of Salamancawith a 3-month history of progressive
dyspnea and angina pectoris on exertion. On admission,
physical examination laboratory findings and electrocardio-
gram did not revealed abnormalities. An echocardiogram
showed a 23 2-cmmobile mass located immediately above
the aortic valve in contact with the aortic root wall (Figure 1,
A). The aortic valve looked normal and had amild central re-
gurgitation jet. A dilatation of the ascending aorta also was
noted, and an enhanced computed tomography was indi-
cated. Computed tomography images confirmed the pres-
ence of a small mass inside the aortic root lumen,
apparently attached to the aorticwall next to the commissure
between the right and noncoronary sinuses (Figure 1, B). An
ascending aorta diameter of 50 mmwas verified. Because of
the unpredictable risk of embolism and the patient’s symp-
toms, an urgent surgical correction was indicated.
A median sternotomy was performed, and standard
cardiopulmonary bypass was established with cannulation
of the proximal aortic arch and the right atrium. The distal
ascending aorta was crossclamped, and the heart was
arrested using antegrade and retrograde blood cardioplegia.
The ascending aorta was resected from the sinotubular
junction to 1 cm proximal to the brachiocephalic trunk.
The aortic root was then exposed, and an irregular
glistening yellowish-white 2 3 2-cm mass with jellylike
appearance and small nodules on its surface was seen
attached to the aortic wall of the noncoronary sinus,
close to the top of the noncoronary right commissure
(Figure 2, A and B). The aortic valve was tricuspid and
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arteriotomy-based triangular portion of the noncoronary
sinus was excised with the mass (Figure 2, C). The wall
root was reconstructed with a bovine pericardial patch
slightly larger than the aortic defect using a continuous
4-0 polypropylene suture (Figure 2, D). To avoid suturing
close to the commissure, a tissue patch was fixed in part
to the wall of the right coronary sinus. The top of the
commissure was then attached to the pericardial patch
with an additional stitch buttressed in the autologous
pericardium. Because of moderate root dilatation and
central aortic insufficiency, subcomissural triangles were
plicated with 3 Teflon-buttressed 2-0 Ticron stitches (Covi-
dien, Mansfield, Mass). Finally, the ascending aorta was re-
placed using a 28-mm Dacron graft. Transesophageal
echocardiography confirmed the competence of the aortic
valve after surgical procedure.
The tumor excised was friable and had a yellowish and
jellylike appearance (Figure 2, E).When the tumor was sub-
merged in water, it acquired villous on its surface like a sea
anemone (Figure 2, F). Histopathologic examination con-
firmed a papillary fibroelastoma. After the operation, the
patient had an uneventful recovery and was discharged
10 days after surgery. Postoperative echocardiography
showed a well-functioning aortic valve.DISCUSSION
Papillary fibroelastomas are the second most common
cardiac tumors, although they represent only less than
10%.1 Although myxomas typically originate from the
atrial wall, the papillary fibroelastomas usually grow
on the valvular endocardium, mainly settled on the aor-
tic, mitral, and tricuspid valves. The nonvalvular endo-
cardial location is rare, and fibroelastomas are rarely
found along the atrial or ventricular walls.2 To
the best of our knowledge, only 1 case of papillary
fibroelastoma originating from the aortic wall has been
reported.3
Because of higher-resolution imaging techniques and
the widespread use of echocardiography, these cardiac
tumors are increasingly found and usually discovered inci-
dentally. Transesophageal echocardiography usually is suf-
ficient to achieve a diagnosis. Symptoms associated with
this tumor are variable. The majority of patients remain
asymptomatic, but serious complications also could pres-
ent in terms of transient ischemic attack, stroke, angina,
myocardial infarction, or sudden death.2,4 Differential
diagnosis includes infective vegetations, thrombi, and
other cardiac tumors. Fibroelastomas are treated on theardiovascular Surgery c Volume 146, Number 1 e1
FIGURE 1. A, Transesophageal echocardiography focuses on the aortic root. A, Mobile mass 23 2 cm is attached to the aortic valve immediately over the
aortic valve (arrow). B, Enhanced computed tomography scan showing the tumor inside the lumen of aortic root as an intraluminal filling defect (arrow).
LA, Left atrium; LV, left ventricle; AV, aortic valve; AA, ascending aorta; RCS, right coronary sinus; NCS, noncoronary sinus; LCS, left coronary sinus.
Case Reportsbasis of symptoms or to prevent potential complications.
Surgical resection is strongly advocated when the tumor
is located in the left side of the heart because of the
risk of cardioembolic complications.4,5 Because of the
tumor’s benign nature, a simple excision usually isFIGURE 2. A, Intraoperative findings of the yellowish mass over the aortic va
after complete resection of tumor with its implant surface. The aortic valve rem
restoring aortic root (arrow). E, Macroscopic view of surgical specimen show
changed in water to its characteristic villous, arboreus, and sea anemone–like ap
ing aorta; AV, aortic valve; RC, right coronary; RCS, right coronary sinus; LCS
e2 The Journal of Thoracic and Cardiovascular Surgeenough, but careful resection is needed to avoid
fragmentation of tumor tissue.
Additional surgical techniques may be required only
in those cases with involvement of valves or other cardiac
structures.1,4 An intraoperative finding of a gelatinouslve (arrow). B, Closer intraoperative view. C, Aortic wall defect remaining
ains intact after resection. D, Triangle-shaped bovine pericardial used for
ing the friable and glistening jellylike appearance of tumor. F, The tumor
pearance, suggesting the diagnosis of papillary fibroelastoma. AA, Ascend-
, left coronary sinus; NCS, noncoronary sinus; LC, left coronary.
ry c July 2013
Case Reportsyellowish mass and its characteristic change of appearance
when submerged in water to a villous sea anemone–like
tumor suggests the diagnosis of papillary fibroelastoma.
However, the definitive diagnosis is confirmed by
histopathologic examinations after surgery.CONCLUSIONS
We present an exceptional case of a papillary fibroelas-
toma originating from the aortic wall of the noncoronary
sinus. The patient was successfully managed with a valve-
sparing procedure. No aortic regurgitation was detected
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implantation for failed bioprosthesisGino Gerosa, MD,a Augusto D’Onofrio, MD,a Chiara Tessari, MD,a Demetrio Pittarello, MD,b
Maurizio Rubino, MD,a and Andrea Colli, MD, PhD,a Padua, ItalyTranscatheter valve-in-valve replacement is a reliable ther-
apeutic option for degenerated bioprosthetic heart valves in
high-risk patients. Successful transfemoral and transapical
techniques have been described for aortic, mitral, and
pulmonary bioprostheses. To the best of our knowledge,
few cases of transcatheter valve-in-valve tricuspid valve
implantation have been reported.1-3
Van Garsse and colleagues1 described the deployment of
the prosthesis via the right internal jugular vein with
ventricular pacing under cardiopulmonary bypass (CPB)
support via peripheral cannulation. Weich and colleagues2
and Cerillo and colleagues3 delivered the device via the
right internal jugular vein without ventricular pacing.
Hon and colleagues4 and Cheung and colleagues5 deliv-
ered the transcatheter prosthesis via a right thoracotomy and
direct puncture of the right atrium. We present a case of an
‘‘open’’ transcatheter valve-in-valve replacement in a high-
risk patient who required conventional cardiac surgery for
severe dysfunction of the aortic, mitral, and tricuspid heartvalves with a high frailty of right-sided heart structures
because of twice passed tricuspid valve replacement.CLINICAL SUMMARY
The patient is a 66-year-old woman with rheumatic heart
disease who underwent tricuspid valve replacement with
a bioprosthesis (Hancock Medtronic, 27 mm; Medtronic
Inc, Minneapolis, Minn) at 25 years of age. She underwent
reoperation at 39 years of age, and the calcified tricuspid bi-
oprosthesis was replacedwith a new bioprosthesis (Hancock
Medtronic, 29 mm) plus mitral commissurotomy. Six years
later, she underwent percutaneous mitral valvuloplasty for
recurrence of mitral stenosis. At that time, oral anticoagula-
tion was begun for the onset of permanent atrial fibrillation.
During the past 4 years, her clinical condition worsened
with shortness of breath and several hospital admissions
for congestive heart failure despite optimal medical treat-
ment. Transthoracic echocardiography revealed normal
left ventricular systolic function, left and right atrium
dilatation, a calcified tricuspid bioprosthesis with moderate
stenosis (mean gradient 11 mm Hg), severe regurgitation,
moderate mitral valve stenosis (mean gradient, 6 mm Hg),
severe regurgitation, and moderate aortic valve stenosis
(valve area, 0.66 cm2/m2).
A decision was made to replace the tricuspid bioprosthe-
sis and the mitral and aortic valves. The European System
for Cardiac Operative Risk Evaluation I was 31.55%, and
European System for Cardiac Operative Risk Evaluation II
was 36.73%. The patient underwent conventional
cardiac surgery through a median resternotomy, CPB, andardiovascular Surgery c Volume 146, Number 1 e3
